Servier Showcases Neuro-Oncology Advancements at ISPNO 2026 in Sydney

Servier's Neuro-Oncology Leadership at ISPNO 2026

From June 28 to July 1, 2026, Servier Pharmaceuticals will showcase its latest research and advancements in neuro-oncology during the 22nd International Symposium on Pediatric Neuro-Oncology (ISPNO) in Sydney, Australia. This important platform will highlight Servier’s commitment to improving treatment options for pediatric low-grade glioma (pLGG), particularly with its recent addition of OJEMDA® (tovorafenib) to its growing glioma portfolio following the acquisition of Day One Biopharmaceuticals.

Significant Presentations and Findings

Servier’s participation features two key presentations that will share new and updated findings from the pivotal Phase 2 FIREFLY-1 study focusing on children suffering from BRAF-altered pLGG. These presentations aim to reinforce the safety and efficacy of OJEMDA, establishing it as a potential standard treatment for children facing relapsed or refractory cases of this type of cancer.

Elly Barry, MD, Chief Medical Officer of Day One Biopharmaceuticals and integral to Servier, expressed the company’s commitment to this cause: “Our upcoming presentations at ISPNO 2026 will help strengthen the robust body of evidence supporting OJEMDA, underlining our commitment to supporting children and their caregivers.”

Among the findings to be presented include updated three-year follow-up growth recovery data. Most notably, the analysis indicates that children with BRAF-altered pLGG who experienced a diminished growth rate during OJEMDA treatment showed a pattern of recovery after discontinuing the treatment—a promising indicator for future therapeutic approaches.

Additionally, a separate examination of the same three-year follow-up data will assess the influence of prior therapies on the effectiveness of OJEMDA in pLGG patients. Results show that patients who have not received prior MAPK inhibitors experienced increased clinical benefits, leading to further exploration of this drug's long-term efficacy across various treatment lines.

Caregiver Communication Insights

Servier will also unveil findings from a significant survey focusing on caregiver experiences when communicating with healthcare providers about pLGG diagnoses. Caregivers in the United States were surveyed to gather insights into communication methods used at diagnosis. Findings from this initiative aim to identify areas that demand improvement in caregiver-provider interactions, thereby enhancing trust and communication effectiveness.

By pinpointing both the efficient and challenging facets of these interactions, the survey highlights critical opportunities for enhancing caregiver trust and confidence during the diagnosis and decision-making process.

OJEMDA: A Breakthrough Treatment

Tovorafenib (OJEMDA®) is classified as a Type II RAF kinase inhibitor that targets mutant BRAF V600, wild-type BRAF, and wild-type CRAF kinases. Specifically designed for treating pediatric patients aged six months and older with relapsed or refractory pLGG, OJEMDA has been approved for its usage based on its substantial response rate. Currently, it holds several critical designations, including Breakthrough Therapy and Rare Pediatric Disease designations from the FDA.

Prior to OJEMDA’s introduction, regulatory approvals for treatments targeting BRAF-driven pLGG were nonexistent, highlighting the significance of this innovation in oncology. Pediatric low-grade gliomas, characterized by their chronic nature and potential for serious side effects, affect the vital development and quality of life of young patients. Comprehensive treatment avenues such as OJEMDA are crucial for improving therapeutic outcomes.

An Ongoing Commitment

As an independent pharmaceutical group with over 20,000 employees, Servier is deeply committed to therapeutic development in areas of high medical need such as oncology and neurology. Following its recent advancements in research for pediatric gliomas, Servier aims to provide more targeted therapies, identifying genetic mutations crucial in cancer management.

With nearly 20% of its revenue invested in research and development, Servier continues to strengthen its role as a leading player in the global oncology landscape, striving to create innovative solutions specifically for patients battling rare cancers. This commitment is poised to pave the way for future advancements in treatment options for pediatric cancers, benefiting both patients and their families significantly.